Eli Lilly announced that retatrutide, its investigational triple agonist targeting GIP, GLP-1 and glucagon receptors, achieved an average weight loss of 16.8% in a Phase 3 trial for type 2 diabetes treatment. The first-in-class drug represents a novel approach combining three hormone pathways in a single therapeutic.
The Phase 3 trial met both primary and key secondary endpoints, with retatrutide delivering superior A1C reduction alongside the significant weight loss results. The study focused on patients with type 2 diabetes, though specific patient population details were not disclosed in the announcement.